Steady 10% growth masked by interest benefit; biosimilars on track, Syngene drags

Delivered ₹4,336 Cr, YoY +10.0%

Actual delivered PAT ₹136.8 Cr, YoY +53.4%. Call framed ₹145 Cr 'before exceptionals', masking ₹8.2 Cr non-recurring charge.

Biosimilar EBITDA margin 25%, vs normalized FY26 baseline 24-25%. On-target, not upgraded.

Interest fell ₹280 Cr → ₹213 Cr YoY = 23.9% reduction. Prior guidance ~₹300 Cr annualized savings; tracking ~₹270 Cr.

Aflibercept launched this month; remaining products (Aspart, Ustekinumab, Denosumab, Bevacizumab) in 'active conversations' for Jul-Sep payor window. Unproven.

Confirmed: Q4 ~4.5% implied, Q1 7% = 250 bps gain from synergies and R&D repriorization.

Syngene down 16% YoY; guided single-digit full-year degrowth + mid-20s EBITDA margins by FY28. New management, cost cuts ongoing, but no near-term inflection priced.

Management pushed back on analyst expectation of 27% (last year's Q3 anomaly). Normalized FY26 was 24-25%. 25% in Q1 is on-track, not an upgrade. Margin expansion contingent on new product mix, not a raised floor.

New phrasing from this call; no prior quarter had quantified H2 target. Five products named for ramp. Execution-dependent, not a hard guidance shift.

Reiterated from prior commentary. Revenue decline in H1, partial recovery in H2. No change to FY27 single-digit degrowth or FY28 return-to-growth narrative.

Q1 quarterly rate (₹213 Cr) annualizes to ~₹852 Cr. YoY comparison: 4*₹280=₹1,120 Cr prior year, saving ~₹268 Cr. On-track to hit or slightly beat ₹300 Cr guidance by FY27-end if debt continues to reduce. Guided range maintained.

Liraglutide contribution single digits this quarter. Base business single-digit growth. No competitive intensity; R&D repriorized to business growth rate. Opex synergies offset R&D reduction.

Mid-20s is our target; 27% last year was Q3 anomaly due to higher North America allocation. Normalized FY26 was 24-25%. New products will have higher margins. Mid-20s guidance maintained.

Biosimilar acceptance myth in ophthalmology now busted. Active contracts in place. Good start out of gates, ramp toward H2. Payor model is fee-for-service Part B.

Biopharm is 83% of business; services only 17%. Main growth engine is biosimilars. Syngene's temporary decline will not materially impact group.

Five products will drive growth; July-Sep payor window finalized for full year. In good place for contracts. Ustekinumab had tremendous offtake past year. Aspart in transition to commercial. Premature to disclose exact terms.

Fulphila 8 years in market, holds 4-5% market share, enduring margins. Ogivri strong in HER2 space. Insulin launched late 2020, holds market responsibly. Adalimumab very strong in Europe despite competition; quality and supply reliability drive loyalty.

API-formulation split 60:40 this quarter (historically 67-33). Profitability agenda across all businesses; not guiding specifically. New launches, cost work, opex cuts, R&D prioritization will drive margin expansion.

No specific number called out for cost drag. Improvements from API pricing premium, R&D portfolio optimization, opex synergies. New units will contribute meaningfully as utilization improves.

Not cutting muscle, cutting fat. Synergies in operations, commercials, enabling functions. Marketing spend on new launches offset by revenue increase. Will be calibrated and mindful.

Inventory buildup for H2 ramp in biosimilars and generics. Shows confidence in scale-up. DIO normalized from 400+ to 280-290. Debt tied to WC, not term loans. Year-on-year interest down 23%.

Current tariff announcement is tweet; generics/biosimilars exempt by law. Would need legislation change. Bipartisan support for affordability. Will watch space. No plans to increase US capex; will use partnerships.

Small holding; not contemplating monetization at this moment. Bicara doing well; will monetize at right time.

Aflibercept launched Aug 2026; Aspart, Ustekinumab, Denosumab, Bevacizumab in active payor negotiations (Jul-Sep cycle). Timing and uptake execution-dependent.

Q1 hit 25%; management defended mid-20s vs analyst expectation of higher. Normalized FY26 was 24-25%. New products carry higher margins.

Q1 at 7% (+250 bps QoQ). Liraglutide scaled-up; peptide/fermentation platform maturing. Path to double-digit EBITDA margin via volume leverage.

FY27 is transition year, single-digit revenue degrowth, margins ~12%. New management, cost reductions, AI (SynAI) platform improvements expected to restore FY28 growth.

Malaysia insulin facility expansion complete (second line approved). US manufacturing via partnerships, not new capex. Capital allocation to debt reduction.

Aflibercept, Aspart, Ustekinumab, Denosumab, Bevacizumab all ramping simultaneously. Payor cycle is Jul-Sep. Any delay in contract finalization or uptake shortfalls will push revenue recognition to FY28.

Syngene down 16% YoY due to lower offtake from key biologics client. Guided single-digit full-year degrowth, but client engagement could be structural, not transient. New management in place to restore momentum, but unproven.

Management acknowledged 'price erosion is real' and competitive forces will happen. Five new products ramping simultaneously could lead to pricing pressure if market uptake is slow or if competitors undercut. Mid-20s margin target could be pressured.

Net debt increased ₹1,100 Cr QoQ due to inventory buildup for H2 ramp. If new product uptake is delayed or slower than expected, inventory could deteriorate, forcing writedowns and further debt deterioration.

Trump administration announced tariff plan; generics and biosimilars are currently exempt by law, but legislation could change. Would increase input costs and reduce pricing power.